The Bioenergetic Health Index: a new concept in mitochondrial translational research

Balu K. Chacko, Philip Kramer, Saranya Ravi, Gloria A. Benavides, Tanecia Mitchell, Brian P. Dranka, David A. Ferrick, Ashwani K. Singal, Scott W. Ballinger, Shannon M. Bailey, Robert W. Hardy, Jianhua Zhang, Degui Zhi, Victor Darley‐UsmarClinical 2014 · DOI

TL;DR

This paper introduces the Bioenergetic Health Index (BHI), a novel metric derived from cellular respiration profiles, to assess mitochondrial health. The BHI aims to serve as an early, sensitive, and dynamic biomarker for a range of chronic diseases, offering potential for improved diagnosis and prognosis.

What Problem Does This Paper Address?

Chronic diseases like diabetes, cardiovascular disease, and cancer are increasingly prevalent, often stemming from underlying metabolic dysfunctions. Mitochondria, the powerhouses of our cells, are central to these processes and can act as early indicators of cellular stress and dysfunction. However, there's a critical need for a simple, integrated clinical test to quantify this "energetic health" in patients. Current methods are either too complex, not sensitive enough, or not readily applicable in a clinical setting. This paper proposes the BHI as a solution to bridge this gap, offering a way to translate complex mitochondrial function measurements into a single, clinically relevant number.

Methods

The core of the proposed method involves measuring cellular oxygen consumption rate (OCR) using a Seahorse XF Analyzer. This is achieved by sequentially adding well-characterized mitochondrial inhibitors: oligomycin (to inhibit ATP synthase), FCCP (an uncoupler to determine maximal respiration), and antimycin A (to inhibit Complex III of the electron transport chain and measure non-mitochondrial respiration). This process generates a detailed "bioenergetic profile" for a given cell type, revealing parameters such as basal respiration, ATP-linked respiration, proton leak, maximal respiration, and reserve capacity.

The novel aspect is the calculation of the Bioenergetic Health Index (BHI) from this profile. The authors propose a formula, derived using linear discriminant analysis (LDA), that integrates these parameters. The proposed BHI equation is:

$BHI = \log \frac{(\text{reserve capacity})^a \times (\text{ATP-linked})^b}{(\text{non-mitochondrial})^c \times (\text{proton leak})^d}$

Here, the exponents (a, b, c, d) are weights determined by fitting the bioenergetic responses to specific conditions (like oxidative stress) to maximize contrast between different states. This weighting allows for customization based on the relative biological significance of each parameter for a particular cell type or disease context.

Datasets

The paper describes experiments using human monocytes isolated from healthy volunteers. These cells were subjected to oxidative stress using 4-HNE (4-hydroxynonenal), a lipid peroxidation product, to test the responsiveness of the BHI. The authors also refer to previous work using platelets, lymphocytes, and neutrophils, suggesting the BHI can be applied to various cell types. No large-scale clinical datasets were used for the initial validation of the BHI concept in this hypothesis paper.

Key Insights and Ideas

  • Mitochondria as "Canaries in the Coal Mine": The paper strongly emphasizes the concept of mitochondria as early warning systems for cellular stress and disease progression, even before overt clinical symptoms appear.
  • Integrated Bioenergetic Profile: Moving beyond single-point measurements, the BHI integrates multiple facets of mitochondrial function (respiration, ATP production, leak, and non-mitochondrial processes) into a single, comprehensive metric.
  • Translational Potential: The BHI is designed to be measured in easily accessible cells from blood (platelets and leucocytes), making it a promising candidate for a clinically applicable biomarker.
  • Dynamic and Sensitive: The BHI is proposed to be a dynamic measure, reflecting real-time changes in cellular energy metabolism in response to stress, disease, and treatment. Its sensitivity to oxidative stress, as demonstrated in monocytes, highlights its potential for early detection.
  • Prognostic Value: The BHI's ability to identify a "progressive deterioration in bioenergetic health" even when cells can still meet basic energy demands suggests it can predict future disease progression or treatment response.

Key Results

The paper demonstrates that the BHI is responsive to oxidative stress. In experiments with human monocytes treated with 4-HNE, a decrease in BHI was observed, correlating with reduced reserve capacity, lower ATP-linked respiration, and increased proton leak. This experimental validation supports the hypothesis that the BHI can indeed quantify changes in bioenergetic health under stress. The authors also highlight that the BHI can be tailored by adjusting the weighting of different parameters (exponents a, b, c, d) based on their relevance to specific pathologies or cell types.

Limitations and Future Work

The authors acknowledge that this paper presents a "Hypothesis" and introduces one possible formulation of the BHI equation. They emphasize that the precise formulation of the BHI will require extensive clinical trials involving normal subjects and patients, along with sophisticated informatics analysis. Future work will focus on:

  • Clinical Validation: Conducting large-scale clinical trials to establish the BHI's diagnostic and prognostic value across various diseases.
  • Refining the BHI Equation: Exploring different mathematical approaches and parameter weightings to optimize the BHI for specific clinical applications and cell types.
  • Expanding Measurement Parameters: Investigating the inclusion of other cellular energetic parameters, such as glycolysis and response to different substrates, into the BHI calculation.
  • Investigating mtDNA Haplotypes: Exploring potential relationships between the BHI and mitochondrial DNA (mtDNA) haplotypes, which can influence individual bioenergetic profiles.

Summary updated

Abstract

Bioenergetics has become central to our understanding of pathological mechanisms, the development of new therapeutic strategies and as a biomarker for disease progression in neurodegeneration, diabetes, cancer and cardiovascular disease. A key concept is that the mitochondrion can act as the 'canary in the coal mine' by serving as an early warning of bioenergetic crisis in patient populations. We propose that new clinical tests to monitor changes in bioenergetics in patient populations are needed to take advantage of the early and sensitive ability of bioenergetics to determine severity and progression in complex and multifactorial diseases. With the recent development of high-throughput assays to measure cellular energetic function in the small number of cells that can be isolated from human blood these clinical tests are now feasible. We have shown that the sequential addition of well-characterized inhibitors of oxidative phosphorylation allows a bioenergetic profile to be measured in cells isolated from normal or pathological samples. From these data we propose that a single value-the Bioenergetic Health Index (BHI)-can be calculated to represent the patient's composite mitochondrial profile for a selected cell type. In the present Hypothesis paper, we discuss how BHI could serve as a dynamic index of bioenergetic health and how it can be measured in platelets and leucocytes. We propose that, ultimately, BHI has the potential to be a new biomarker for assessing patient health with both prognostic and diagnostic value.
BibTeX
@inproceedings{chacko2014bioenergetic,
  author = {Balu K. Chacko and Philip Kramer and Saranya Ravi and Gloria A. Benavides and Tanecia Mitchell and Brian P. Dranka and David A. Ferrick and Ashwani K. Singal and Scott W. Ballinger and Shannon M. Bailey and Robert W. Hardy and Jianhua Zhang and Degui Zhi and Victor Darley‐Usmar},
  title = {{The Bioenergetic Health Index: a new concept in mitochondrial translational research}},
  booktitle = {Clinical},
  year = {2014},
  doi = {10.1042/cs20140101},
}
Figure